NCT04256317 2026-03-18
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
Clinical Trials
6 trialsNCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT07060001 2026-03-06
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
Phase 2 Not yet recruiting
NCT02530463 2026-03-05
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07439211 2026-03-03
GAVEL
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07148180 2026-02-05
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
Phase 1/2 Recruiting